With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...

On Saturday, GSK announced full results from the ANCHOR-1 and ANCHOR-2 phase 3 trials of depemokimab versus placebo (both with the standard of care [SOC]) in adults with CRSwNP. ANCHOR-1 (N=271 ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

(RTTNews) - GSK plc (GSK.L, GSK) announced that Depemokimab demonstrated clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, obstruction, and asthma exacerbations compared to placebo. The FDA has accepted GSK’s ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab ...

According to InvestingPro analysis, GSK currently appears undervalued, suggesting potential upside for investors interested in this development. The applications pertain to the use of depemokimab as ...